Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: A case report

Cases Journal

Volumn 2, Issue 7, 2009, Pages

  Verma, Rajanshu ^a   Dhamija, Radhika ^a   Batts, Donald H ^a   Ross, Stephen C ^a   Loehrke, Mark E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; LIVER ENZYME; MOXIFLOXACIN;

ABDOMINAL TENDERNESS; AGED; ARTICLE; BLOOD DYSCRASIA; CASE REPORT; CHRONIC BRONCHITIS; DISEASE EXACERBATION; FATALITY; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; MALE; PATIENT MONITORING;

EID: 77953401878     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-8063     Document Type: Article

References (15)

1. Bayer Corp: Avelox (Moxifloxacin HCl) package insert. Apr 2001.
2. Nori S, Nebesio C, Brashear R, Travers JB: Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. Arch Dermatol 2004, 140:1537-1538.
3. Soto S, López-Rosés L, Avila S, Lancho A, González A, Santos E, Urraca B: Moxifloxacin-induced acute liver injury. Am J Gastroenterol 2002, 97:1853-1854.
4. Pugh AJ, Barve AJ, Falkner K, Patel M, McClain CJ: Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis 2009, 13:277-294.
5. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J, Drug Induced Liver Injury Network (DILIN) : Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
6. Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, Chon CY, Han KH, Ahn SH, Jang IJ, Cho JY, Suh Y, Cho MO, Lee JE, Kim KH, Lee MG: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007, 17:403-415.
7. Ahmed S, Vo NT, Thalhammer T, Thalhammer F, Gattringer KB, Jäger W: Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. J Pharm Pharmacol 2008, 60:55-62.
8. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ: Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007, 150:808-815.
9. Son CH, Kim HI, Kim KN, Lee KN, Lee CU, Roh MS, Kim KH, Yang DK, Lee SK: Moxifloxacin-associated drug hypersensitivity syndrome with drug-induced hypersensitivity pneumonitis. J Investig Allergol Clin Immunol 2008, 18:72-73.
10. González I, Lobera T, Blasco A, del Pozo MD: Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. J Investig Allergol Clin Immunol 2005, 15:146-149.
11. Prins JM, Koopmans RP: Novel side effects of moxifloxacin: making a balanced decision again. Ned Tijdschr Geneeskd 2008, 152:1862-1864.
12. Chang CM, Lee NY, Lee HC, Lee IW, Wu CJ, Lin YS, Ko WC: Moxifloxacin-associated neutropenia in a cirrhotic elderly woman with lower extremity cellulitis. Ann Pharmacother 2008, 42:580-583.
13. Wong HY, Chau CH, Yew WW: Moxifloxacin-induced arthropathy. Int J Tuberc Lung Dis 2007, 11:117.
14. Gavin JR 3rd, Kubin R, Choudhri S, Kubitza D, Himmel H, Gross R, Meyer JM: Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004, 27:671-686.
15. Carrión Valero F, Fácila Rubio L, Marín Pardo J: Syncope after administration of moxifloxacin. Arch Bronconeumol 2000, 36:603-604.